Anavex Life Sciences Corp (AVXL)

[nidan7500]

Today's seeking Alpha article makes it very clear that the FDA has gone down the wrong STAT-SPEAK path and that the real tool-suite discussed here yesterday is far better when assessing AD trial results. IMO.

Yes, this new biomarker analysis technology has been licensed to a young company, Ampera Life.

https://www.amperalife.com/

That’s good news. To be used the technology must be commercially available. Not possible with a mere prototype device used only to demonstrate the technology, resting on the bench of some university lab (in this case UC Sand Diego). With this contractual arrangement, Ampera can manufacture the devices that can be used in up-coming clinical trials.

Using the new biomarker analysis device wouldn’t it be interesting to see the data from a clinical Alzheimer’s trial comparing blarcamesine with Aricept, Aduhelm, Leqembi, or any of the others so wonderfully approved for clinical use.

WGT